Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01460160 · ClinicalTrials.gov registry record · Phase 2
Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia
A Phase 2 study of Leukemia, Pediatric, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 106
- Enrollment target
- 20
- Study locations
NCT01460160 is a Phase 2 study of Leukemia, Pediatric that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 106 participants. The trial reports 20 study locations across 9 states.
The verdict
NCT01460160, a Phase 2 study of Leukemia, Pediatric, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 106 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether Dasatinib when added to standard chemotherapy is effective and safe in the treatment of pediatric philadelphia chromosome positive acute lymphoblastic leukemia
Conditions Studied
Interventions
- DRUG Dasatinib
Study Locations (20)
California
- Antranik Agop Bedros - Loma Linda
- Miller Children's and Women Hospital - Long Beach
- Children'S Hospital Of L.A. - Los Angeles
- Southern California Permanente Medical Group - Los Angeles
- Valley Children's Hospital - Madera
- Children's Hospital of Orange County - Orange
- Lpch & Sumc - Palo Alto
- Kaiser Medical Center - Roseville
- Ucsf - Hematology/Oncology - San Francisco
Florida
- Lee Memorial Health System - Fort Myers
- University Of Florida - Gainesville
- Nemours Children'S Clinic - Jacksonville
- Md Anderson Cancer Center Orlando - Orlando
Alabama
- University Of Alabama At Birmingham - Birmingham
Arizona
- Phoenix Children'S Hospital/Ctr. For Cancer & Blood Ctr. - Phoenix
Arkansas
- University Of Arkansas For Medical Sciences - Little Rock
Colorado
- Children'S Hospital Colorado - Aurora
Connecticut
- Connecticut Children's Medical Center - Hartford
Delaware
- A. I. Dupont Hospital For Children - Wilmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2012-04-13 |
| Est. Completion | 2021-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01460160
The ClinicalTrials.gov registry entry for NCT01460160 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Leukemia, Pediatric appearing as the primary indexed condition, and to 1 intervention - of which Dasatinib is the first listed.
NCT01460160 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT01460160 about?
NCT01460160 is a clinical study titled "Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia". The purpose of this study is to determine whether Dasatinib when added to standard chemotherapy is effective and safe in the treatment of pediatric philadelphia chromosome positive acute lymphoblastic leukemia
What is the current status of trial NCT01460160?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 106 participants. The study started on 2012-04-13. Estimated completion is 2021-06-01.
What conditions does trial NCT01460160 study?
This clinical trial studies the following conditions: Leukemia, Pediatric.
What interventions are being tested in trial NCT01460160?
The interventions under investigation include: Dasatinib (DRUG).
Who is sponsoring clinical trial NCT01460160?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01460160 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.